---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106525"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:10:08.012552+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics Q2 revenue $26.8M (+6% YoY); net income falls to $1.6M; CEO transition

## Summary
- GAAP net income of $1.6M ($0.00 EPS) vs $4.5M in Q2 2024; H1 net income $5.3M vs $14.5M.
- Revenue Q2 $26.8M, up from $25.2M; H1 $48.8M, down from $52.4M due to ETUARY decline and new product launches.
- Full-year revenue guidance reaffirmed at $118-128M (11-21% growth). Non-GAAP adj. net income Q2 $2.9M vs $3.1M.
- CEO Han Ying resigned, becomes SVP Science; Executive Chair Ping Zhang appointed interim CEO.
- Pipeline: Positive Phase 3 Hydronidone data; NDA filing with NMPA expected Q3 2025. Launched Etorel in June.

## SEC filing metadata
- accession: 0000950170-25-106525
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000095017025106525/0000950170-25-106525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000095017025106525/gyre-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106525
- JSON: https://secwatch.observer/filing/0000950170-25-106525.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106525.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.